MedPage Today -- A novel formulation of inhaled insulin (Technosphere), when given at meals with bedtime insulin glargine (Lantus), equals twice-daily premixed biaspart insulin (NovoLog) for glucose control in type 2 diabetes, a randomized trial showed.
